Variable | Dutch discovery cohort (n =98) | French validation cohort (n =126) | TCGA confirmation cohort (n =184) |
---|---|---|---|
Gender | Â | Â | Â |
Female | 50 (51%) | 59 (47%) | 93 (51%) |
Age at diagnosis (years) | Â | Â | Â |
Mean | 40.3 | 39.8 | 40.8 |
Median | 39.6 | 39.4 | 39 |
Range | (21-83) | (18-76) | (14-87) |
Duration of follow-up of patients still alive at last evaluation (months) | Â | Â | Â |
Mean | 133.6 | 39.6 | 23.7 |
Median | 129.0 | 30.9 | 10.7 |
Range | 72-288 | 1-187 | 1-185 |
Patients deceased | 46 (47%) | 32 (25%) | 18 (10%) |
Overall survival of patients deceased at last evaluation (months) | Â | Â | Â |
Mean | 89 | 48.6 | 63.5 |
Median | 149.0 | 51.8 | 65.6 |
Range | 1-361 | 0.1-98 | 1.2-132.6 |
Histological subtypes | Â | Â | Â |
Oligodendroglioma | 43 (43%) | 53 (42%) | 87 (47%) |
Astrocytoma | 42 (42%) | 23 (18%) | 40 (22%) |
Oligoastrocytoma | 15 (15%) | 50 (40%) | 57 (31%) |